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5-(O-Perbenzoylated-b-D-glucopyranosyl)tetrazole was obtained from O-perbenzoylated-b-D-glucopyr-
anosyl cyanide by Bu3SnN3 or Me3SiN3–Bu2SnO. This tetrazole was transformed into 5-ethynyl- as well
as 5-chloromethyl-2-(O-perbenzoylated-b-D-glucopyranosyl)-1,3,4-oxadiazoles by acylation with propi-
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1. Introduction
Glycogen phosphorylase (GP) has been a validated target i
combatting type 2 diabetes mellitus1 (for a detailed foundation o
inhibiting liver GP as an investigational concept for lowering bloo
glucose levels, please consult recent review articles2–6). GP is
well-known enzyme that has been investigated by various meth
ods as to its structural features and kinetic behaviour.7,8 By X-ra
crystallographic studies on enzyme–inhibitor complexes severa
binding sites of GP have been discovered and are exploited fo
the design of new antidiabetic agents: the catalytic centre accom
modates mainly glucose derivatives and the inhibitor site bind
aromatic compounds of various ring size and annelation type; clas
0008-6215/$ - see front matter  2011 Published by Elsevier Ltd.
doi:10.1016/j.carres.2011.03.004
⇑ Corresponding authors. Tel.: +36 52512900/22464; fax: +36 52512744 (T.P
tel.: +36 52512900/22348; fax: +36 52512744 (L.S.).
E-mail addresses: tpatonay@puma.unideb.hu (T. Patonay), somsak@tigr
unideb.hu (L. Somsák).
 Visiting scientist. Permanent address: Laboratoire des Glucides-UMR 621
Université de Picardie Jules Verne, Ilot des poulies, 10 rue Baudelocque, 8003
Amiens, France.
1Please cite this article in press as: Kun, S.; et al. Carbohydr. Res. (201yl chloride, respectively. The chloromethyl oxadiazole gave the correspondin
treatment with NaN3. These compounds were reacted with several alkyne
lysed cycloaddition conditions to give, after removal of the protecting group
-D-glucopyranosyl-1,3,4-oxadiazolyl-1,2,3-triazole, b-D-glucopyranosyl-1,2,3
and b-D-glucopyranosyl-1,3,4-oxadiazolylmethyl-1,2,3-triazole type com
was also transformed under the above conditions into a series of aryl-1,3,4
aryl-1,2,3-triazolyl-1,3,4-oxadiazoles, and aryl-1,3,4-oxadiazolylmethy
mpounds were assayed against rabbit muscle glycogen phosphorylase b an
ition constants in the upper micromolar range (2-phenyl-5-[1-(b-D-glucopy
,3,4-oxadiazole 36: Ki = 854 lM, 2-(b-D-glucopyranosyl)-5-[1-(naphthalen-2
oxadiazole 47: Ki = 745 lM).
 2011 Published by Elsevier Lt
siﬁcation of inhibitors binding to other sites such as the allosteri
the new allosteric, and the storage sites is more complex and ca
be found in the review literature.5,9
Among the glucose-based10 inhibitors of GP, the ﬁrst successfu
series was that of the glucosylamides11–14 (Chart 1a, A). Consider
ing the NHCO moiety as a linker (i) between the sugar and the aro
matic part of these compounds several molecules with bioisoster
replacements of the NHCO (see heterocyclic linkers ii–v) wer
designed and synthesized. Kinetic and crystallographic studie
showed a very high resemblance both in strength and structura
features of binding between amides 1 and 2 and 1,2,3-triazoles
3 and 4, respectively.16,17 Constitutional isomeric C-glucopyranosy
oxadiazoles18,19 5–10 showed a strong preference for the 3-ary
5-b-D-glucopyranosyl-1,2,4-oxadiazoles 9 and 10 to exhibit th
highest afﬁnity to GP. N-Acyl-N0-b-D-glucopyranosyl urea derivative
 A very recent report: Anand, N.; Jaiswal, N.; Pandey, S. K.; Srivastava, A. K
Tripathi, R. P. Carbohydr. Res. 2011, 346, 16–25. Indicated weak inhibition of GP by
b-D-glucopyranosyl-1,2,3-triazole derivatives with coumarinyloxymethyl and oth
substituents in the 4-position.1), doi:10.1016/j.carres.2011.03.004
(Chart 1a, B) proved signiﬁcantly better inhibitors than amides A
with the same aglycon5,9 (compare inhibitor constants for 1 and
11 as well as 2 and 12, respectively). Based on the successful bioisos-
80 teric modiﬁcation of amides A we have started a program to synthe-
size a series of glucosyl heterocyclic compounds (Chart 1b) which
can be derived from acyl ureas B by substituting each NHCO moiety
by a heterocycle (linkers 1 and 2). In addition, compounds with a
methylene group between linkers 1 and 2 lending higher ﬂexibility
to the molecules were also designed. In this paper we present our re-
sults in synthesizing 1,2,3-triazole and 1,2,4-oxadiazole linked deriv-
atives of D-glucose. With the aim of targeting the inhibitor site of GP,
compounds with aromatic rings in place of the glucosyl groups were
also synthesized.
90 2. Results and discussion
2.1. Syntheses
Access to suitable precursors to assemble the target oxadiazoles
and triazoles is shown in Scheme 1. The O-perbenzoylated 5-b-D-
glucopyranosyl tetrazole 17 was ﬁrst prepared from 13 by the lit-
erature protocol20 using in situ obtained ammonium azide in DMF
at reﬂux (conditions a). To avoid chromatographic puriﬁcation in
larger scale preparations, two other methods were investigated,
as well. Thus, reaction of 13 with Bu3SnN3 in 1,2-dimethoxyethane
at reﬂux (DME, conditions b) followed by acidic workup21 gave 17
100 in essentially quantitative yield. Another method, applying Me3-
SiN3 and Bu2SnO (conditions c) for in situ generation of dibutyl
trimethylsilyloxytin azide22 was similarly efﬁcient. Conditions a
afforded tetrazoles 18 and 20 from the corresponding nitriles 14
and 16 in good and excellent yields, respectively; however, reac-
tio
of
da
te
co
1105-Substituted tetrazoles can be transformed into 1,3,4-oxadi-
azoles by acylation.23,24 Although acid chlorides are generally
used in such acylations,25 the chloride of propiolic acid is rather
difﬁcult to prepare and extremely sensitive to air. Therefore, the
speciﬁc ethynyl-oxadiazoles 21–24 were prepared by DCC medi-
ated reaction26,19 of propiolic acid with the corresponding tetra-
zoles 17–20 (conditions d) to give the target compounds in
satisfactory yields. Chloroacetyl chloride under conditions e, on
the other hand, furnished the chloromethyl-oxadiazoles 25 and
27 in excellent yields. Replacement of the chloride by azide was
120effected by NaN3 in DMF (conditions f) to give 26 or NaN3–18-
crown-6 in acetone (conditions g) to produce 28 in very high
yields.
Ethynyl-oxadiazoles 21–24 were cyclized with several azides
under variants of the copper(I) catalysed azide–alkyne cycloaddi-
tion (CuAAC) conditions27–29 (Scheme 2). The triazole ring forma-
tion from 21 was similarly efﬁcient by using phenyl azide
(conditions a) or by in situ generation of this reagent from the cor-
responding commercial boronic acid30 (conditions b) to give 29.
The reaction of 21 under conditions a gave high yields of 30 and
13032 from 1-azidonaphthalene and O-peracetylated b-D-glucopyran-
osyl azide,31,32 respectively, and reactions of latter azide with 22–
24 gave very good yields of the respective 35, 39, and 43, too. In the
absence of easily available 2-azidonaphthalene, 31 was obtained
from 21 in a one pot, two-step reaction from naphthalene-2-boro-
nic acid under conditions b. O-Acyl protecting groups were re-
moved by the Zemplén protocol (conditions d) to give test
compounds 36, 40, 44, and 45–48 in very good to excellent yields.
For the transformations of 2-aryl-5-ethynyl-1,3,4-oxadiazoles
22–24 to the corresponding triazoles (33, 37, 41with phenyl azide,
14034, 38, 42with 2-azido-ethanol) addition of TMEDA to the reaction
mixtures (conditions c) proved advantagous and the compounds
we
3)
ev
a) Selected glucose analogue inhibitors of glycogen phosphorylase (GP) (Ki [μM] determined against rabbit 
muscle GPb)
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Pln of 15 to give the 1-naphthyl derivative 19 failed. The reaction
15 with Bu3SnN3 in boiling DME (conditions b) needed three
ys to give 19, but using diglyme as a solvent of higher boiling
mperature diminished the reaction time to two hours with a con-
mitant increase of the yield.ease cite this article in press as: Kun, S.; et al. Carbohydr. Res. (2011), dore isolated in medium to good yields.
CuAAC reaction of 26 with phenylacetylene to give 49 (Scheme
was tried with the Cu(OTf)2–Cu system33 (conditions a); how-
er, conversion of the starting material was not complete in onei:10.1016/j.carres.2011.03.004
ON
1 (5
22 (
3 (
4 (5
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R
13 Bz4-β-D-Glcp 17 (a, 3.5 h, 94%) 2
(b, DME, 24 h, 99%)
(c, 19 h, 95%)
14 Ph 18 (a, 2 h, 69%)
15 1-naphthyl 19 (a, 72 h, traces) 2
(b, DME, 72 h, 73%)
(b, diglyme, 2 h, 86%)
16 2-naphthyl 20 (a, 2 h, 94%) 2
Scheme 1. Reaction conditions: (a) NaN3 (3 equiv), NH4Cl (3 equiv), dry DMF, reﬂ
80 C; (d) HC„C–COOH (2 equiv), DCC (1 equiv), toluene, 80 C, 2 h (reﬂux, 4 h in c
24 h; (g) NaN3 (3 equiv), 18-crown-6 (0.1 equiv), acetone, rt, 2 h.day. Incomplete conversion was also observed in reactions of 26
with ethyl propiolate and propargyl alcohol to give 50 and 51,
respectively, when the more conventional CuSO4–L-ascorbic acid
reagent was used (conditions b). Triazoles 49–50 and azido-
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(3 equiv), CuSO45H2O (0.3 equiv), MeOH, rt, 16 h; (2) L-ascorbic acid (1.5 equiv), 21 (1
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Scheme 3. Reaction conditions: (a) R0–C„CH (1 equiv), Cu(OTf)2 (0.03 equiv), Cu
(0.05 equiv), L-ascorbic acid (0.15 equiv), CH2Cl2/water 1:1, 50 C, 1 d; (c) R0–C„CH
tBuOH–water 1:2, rt 2 h; (d) R0–C„CH (1.2 equiv), CuSO45H2O (0.04 equiv), Na-L-as
(cat.), MeOH, rt; (f) NH3, MeOH, rt; (g) TBAF (0.6 equiv), dry THF, 70 C, 5 h.
Please cite this article in press as: Kun, S.; et al. Carbohydr. Res. (201R O
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of 21); (e) ClCH2COCl (1.1 equiv), PhCH3, reﬂux, 24 h; (f) NaN3 (1 equiv), dry DMF, 50 150methyl-oxadiazole 26 were deprotected by the Zemplén method
(conditions e) to give test compounds 59, 60, 62, and 63,
respectively, while carboxamido triazole 61 was obtained from
50 by NH3 in MeOH (conditions g).
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Pl2-Azidomethyl-5-phenyl-1,3,4-oxadiazole 28 was reacted with
enylacetylene to give triazole 52 with as few as 0.01 M equiv
Cu(I) in the presence of TMEDA (conditions c). Similar reactions
28 with ethyl propiolate, propargyl alcohol, 1,1-dimethyl-prop-
ynol, trimethylsilylacetylene, and 3-amino-phenylacetylene
ding to the corresponding triazoles 52–56 and 58, respectively,
re performed with higher catalyst loading (conditions d) in
me cases with added TMEDA. Removal of the trimethylsilyl
oup from 56 was achieved by TBAF (conditions f) to give 57 in
antitative yield.
Each azide–alkyne cycloaddition was carried out under Cu(I)
talyzed conditions for which formation of 1,4-disubstituted
,3-triazoles with practically exclusive regioselectivity was re-
rted.27–29 The 1,4-substitution pattern was conﬁrmed by the car-
n spectra of the compounds exhibiting characteristic resonances
r C-4 (132–136 ppm in the sugar derivatives, 132–148 ppm for
e aromatic compounds) and C-5 (120–128 ppm for each type)
le 1
luation of the new compounds as inhibitors of rabbit muscle glycogen phosphorylase b
ds
m).Entry
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Determined by the protocol in described in Ref. 12.
Calculated from the IC50 value by the Cheng–Prusoff equation:41 Ki = IC50/(1 + [S]/K
Tested concentration: 625 lM.
Tested concentration: 312.5 lM.ease cite this article in press as: Kun, S.; et al. Carbohydr. Res. (2011), doaccordance with literature precedents reporting signiﬁcantly
gher chemical shift values for the quaternary C-4 as compared
that of C-5.34–37
. Enzyme inhibition studies
The kinetic parameters of the synthesized molecules were
termined according to previously described enzymatic proto-
ls12,38 and the results are summarized in Table 1 showing also
e inhibitory efﬁciency of some reference compounds. Based on
e veriﬁed bioisosteric replacement of NHCO by 1,2,3-triazole
r the glycogen phosphorylase case by enzyme kinetic and X-ray
stallographic investigations16 (cf. Chart 1a, 1–4), the present
dy aimed at double replacement of the NHCONHCO moieties
acyl urea derivatives (compounds in entry 1) by two ﬁve mem-
red heterocycles. Glucosyl-triazolyl-oxadiazoles (entry 2) proved
niﬁcantly weaker inhibitors both in comparison to the acyl
GPb) (Ki [lM] unless otherwise stated) and comparison of inhibition to that of the
R
Others
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15 March 2011ureas (entry 1) and the glucosyl-triazoles in entry 3. This might b
partially attributed to the increased space required for these mo
ecules to get accommodated in the b-channel, a subsite of the ac
tive site: while the phenyl derivative 36 showed weak inhibition
compounds 40 and 44 with the naphthyl moieties were no mor
active. The polar endgroup of 48 was also not favourable for th
binding as it was similarly experienced in a series of glucosyl biure
derivatives.39 Glucosyl-oxadiazolyl-triazoles (entry 4) with a re
versed order of the heterocycles proved similarly weak inhibitor
as their counterparts inentry 2 and also glucosyl-oxadiazoles inen
try 5. In this latter series19 (entry 5) only the methyl derivativ
showed moderate inhibition,20,40 and any increase in the size o
the side chain either by azide substitution in the methyl group a
in 63 or appending a cycle to the oxadiazole as in 5 and 6 prove
detrimental for the binding. Enhancing the ﬂexibility of the agly
con (entry 6) by insertion of a methylene bridge in between th
oxadiazole and the triazole as in compounds 59–62 did no
strengthen binding to the enzyme. The heterocyclic compound
33, 34, 37, 38, 41, 42, and 52–57 (entries 7–9) targeting the inhib
itor site of GP proved also inactive.
3. Conclusion
Synthetic methods using tin azide derivatives adapted for th
synthesis of O-perbenzoylated 5-b-D-glucopyranosyl tetrazol
(17) gave the target compounds in almost quantitative yield. Acy
lations of tetrazole 17 gave ethynyl- and azidomethyl-1,3,4-oxad
azoles (the latter via the chloromethyl compound) whose furthe
transformations under CuAAC conditions gave several variants o
compounds containing a b-D-glucopyranosyl moiety attached t
1,3,4-oxadiazole and 1,2,3-triazole. By using similar chemistry
series of compounds with aromatic rings replacing the b-D-gluco
pyranosyl part was also prepared. Enzyme kinetic measurement
showed the new compounds to have weak or no inhibition toward
rabbit muscle glycogen phosphorylase b, with inhibition constant
for the best inhibitors in the upper micromolar range (36
Ki = 854 lM, 47: Ki = 745 lM). This might be attributed to the siz
of the aglycon in these compounds that exceeds the otherwis
rather ﬂexible space in the b-channel next to the catalytic site o
the enzyme in cases of the sugar derivatives, while the aromat
compounds ﬁt neither in the inhibitor nor in any other binding sit
4. Experimental
4.1. General methods
Melting points were measured in open capillary tubes or on
Koﬂer hot-stage and are uncorrected. Optical rotations were deter
mined on a Perkin–Elmer 241 polarimeter at room temperatur
NMR spectra were recorded with Bruker WP 360 SY (360/90 MH
for 1H/13C) and Varian UNITYINOVA 400 WB (400/100 MHz fo
1H/13C) spectrometers. Chemical shifts are referenced to Me4Si a
the internal reference (1H) or the residual solvent signal (13C
Thin-layer chromatography (TLC) was carried out on aluminium
sheets coated with Silica Gel 60 F254 (Merck). TLC plates were in
spected by UV light (k = 254 nm) and after gentle heating for th
carbohydrate derivatives. Silica gel column chromatography wa
performed with silica gel Si 60 (40–63 lm) purchased from Merc
(Darmstadt, Germany). Organic solutions were dried over anhy
drous MgSO4, and concentrated at diminished pressure at 40
50 C (water bath). 2-Azidoethanol was prepared according t
the literature.42 5-Substituted-tetrazoles 17,20 18,43 and 2043 wer
prepared by the Finnegan procedure44 from the corresponding n
triles 13,45 15,46 and 16,47 respectively. 2-Chloromethyl-5-pheny
1,3,4-oxadiazole 27 was obtained by the literature protocol.26Please cite this article in press as: Kun, S.; et al. Carbohydr. Res. (2014.2. General procedure for the Zemplén deacylation
An O-peracylated compound (100 mg) was dissolved in dr
MeOH (1 mL) and a solution of NaOMe (1 M in MeOH) was adde
to the solution in a catalytic amount. The reaction mixture wa
kept at rt. When the reaction was complete (TLC, 7:3 CHCl3–MeOH
the solution was neutralized with a cation exchange resin Amber
lyst 15 (H+ form). Filtration and removal of the solvent resulted i
the corresponding deacetylated sugar derivative, which, if neces
sary, was puriﬁed by column chromatography.
4.3. General procedure for the synthesis of 5-substituted-
tetrazoles by using Bu3SnN3
A nitrile was dissolved in DME or diglyme and 3 equiv o
Bu3SnN3 were added. The mixture was stirred and heated at reﬂu
for the given time while the reaction was monitored by TLC (4:
PhCH3–EtOAc) to indicate completion of the transformation. The
it was cooled to rt and toluene and aq HCl (4 M solution) wer
added and themixture was stirred for 2 h. The precipitated produc
was ﬁltered, washed with water, and dried. The two phas
ﬁltrate was separated, the organic phase was diluted by hexan
to precipitate a further crop of the product which was ﬁltere
and dried.
4.3.1. 5-(20,30,40,60-Tetra-O-benzoyl-b-D-glucopyranosyl)-
tetrazole (17)
(i) Prepared by general procedure 4.3 from 1345 (4.0
6.6 mmol) in diglyme (50 mL), reaction time 26 h. After the worku
the precipitate was washed with hot hexane to give 17 (4.24
99%) as a white solid.
(ii) A solution of 1345 (1.00 g, 1.65 mmol), Me3SiN3 (434 l
3.3 mmol) and Bu2SnO (41 mg, 0.16 mmol) in dry toluen
(30 mL) was heated for 19 h at 80 C. Toluene was removed unde
reduced pressure, the residue was dissolved in MeOH and concen
trated again. The residue was dissolved in EtOAc (15 mL), extracte
with satd aq NaHCO3 soln (2  15 mL). The combined organ
phases were dried, and then concentrated to a syrup that was tri
urated in hexane to give 17 (1.02 g, 95%) as an amorphous whit
solid.
The material obtained by both methods had spectral character
istics identical with the reported ones.20
4.3.2. 5-(Naphthalen-1-yl)-tetrazole (19)
Prepared by general procedure 4.3.1 from compound 15 (3.68
24 mmol) and Bu3SnN3 (19.8 mL, 24 g, 72 mmol) in diglym
(70 mL). Reaction time 2 h. Product 19 (1.30 g, 86%) was obtaine
as white crystals. Mp: 216–218 C (lit.48 mp 165 C). 1H NM
(Me2SO-d6, 360 MHz) d (ppm): 7.65–7.75 (3H, m, H-30, H-70, H
80), 8.02 (1H, d, J = 7.1 Hz, H-20), 8.10 (1H, d, J = 7.7 Hz, H-40), 8.2
(1H, d, J = 8.2 Hz, H-60), 8.6 (1H, d, J = 8.1 Hz, H-90), 17.0 (1H,
NH-1). 13C NMR (DMSO-d6, 90 MHz) d (ppm): 121.9 (C-10), 125.
(C-40), 125.8 (C-60), 127.2 (C-20), 128.2 (C-30), 128.9 (C-70), 129.
(C-80), 130.4 (C-50), 131.9 (C-90), 133.8 (C-100), 165.3 (C-1). Ana
Calcd for C11H8N4 (196.07): C, 67.34; H, 4.11; N, 28.55. Found: C
67.16; H, 4.19; N, 28.48.
4.4. General procedure for the synthesis of 2-ethynyl-5-
substituted-1,3,4-oxadiazoles
Propiolic acid was dissolved in dry toluene and DCC was added
The precipitated dicyclohexylurea (DCU) was ﬁltered off an
washed with dry toluene. The combined ﬁltrate was added to
solution of a tetrazole 17–20 in dry toluene. This mixture was stir
red at the given temperature. When the reaction was complet
(TLC 1:1 EtOAc–hexane for 21, 10:1 PhCH3–MeOH for 22–24) th1), doi:10.1016/j.carres.2011.03.004
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Pllvent was evaporated and the residue was puriﬁed by column
romatography (eluent PhCH3 unless stated otherwise).
.1. 2-(20,30,40,60-Tetra-O-benzoyl-b-D-glucopyranosyl)-5-
hynyl-1,3,4-oxadiazole (21)
Prepared by general procedure 4.4 from 17 (1 g, 1.57 mmol),
opiolic acid (220 mg, 3.14 mmol) and DCC (320 mg, 1.57 mmol)
14 mL abs toluene at reﬂux for 4 h. Column chromatography
:7 EtOAc–hexane) and crystallization from EtOH gave 21
15 mg, 59%) as white crystals. Rf = 0.75 (1:1 EtOAc–hexane),
p: 132–135 C, [a]D = 151 (c 0.18, CHCl3), 1H NMR (CDCl3,
0 MHz) d (ppm): 8.05–7.81 (8H, m Ar), 7.57–7.25 (12H, m, Ar),
9 (1H, t, J = 9.3, Hz, H-20 or H-30 or H-40), 5.87–5.81 (2H, m,
9.3, 10.6 Hz, 2 of H-20 or H-30 or H-40), 5.22 (1H, d, J10 ,20 = 10.6 Hz,
10), 4.67 (1H, dd, J50 ,60a = 2.6 Hz, J60a,60b = 11.9 Hz, H-60a), 4.52 (1H,
, J50 ,60b = 5.3, J60a,60b = 11.9 Hz, H-60b), 4.35 (1H, ddd, J50 ,40 = 9.3 Hz,
,60a = 2.6 Hz, J50 ,60b = 5.3 Hz, H-50), 3.57 (1H, s, ethynyl-H). 13C
R (CDCl3, 90 MHz) d (ppm): 165.3, 165.1, 164.6, 164.4 (CO),
2.0, 150.0 (oxadiazole), 133.9–128.0 (Ar), 90.9 (C„CH), 75.1,
.2, 70.4, 69.6, 68.6 (C-10–C-50), 66.7 (C„CH), 62.6 (C-60). Anal.
lcd for C38H28N2O10 (672.65): C, 67.85; H, 4.20; N, 4.16; O,
.79. Found: C, 67.78; H, 4.15; N, 4.10.
.2. 2-Ethynyl-5-phenyl-1,3,4-oxadiazole (22)
Prepared by general procedure 4.4 from propiolic acid (3.81 g,
mmol), DCC (5.62 g, 27 mmol) in toluene (25 mL, than washing
th 25 mL) and 18 (4.00 g, 27 mmol) in toluene (100 mL). Stirring
80 C for 1.5 h. Column chromatography gave 22 (2.50 g, 47%) as
ite crystals. The compound is light sensitive therefore it must be
red in a dark and cold place. Mp: 106–110 C; 1H NMR (Me2SO-
, 360 MHz) d (ppm): 3.62 (1H, s, C„CH), 7.47–7.57 (3H, m, H-30,
40, H-50), 8.04 (2H, dd, J = 7.0 Hz, 1.6 Hz, H-20, H-60). 13C NMR
e2SO-d6, 90 MHz) d (ppm): 67.6 C„CH), 85.9 (C„CH), 122.9
-10), 127.1 (C-20, C-60), 129.1 (C-30, C-50), 132.3 (C-40), 149.4 (C-
, 164.7 (C-5). Anal. Calcd for C10H6N2O (170.05): C, 70.58; H,
5; N, 16.46; O. Found: C, 70.46; H, 3.61; N, 16.51.
.3. 2-Ethynyl-5-(naphthalen-1-yl)-1,3,4-oxadiazole (23)
Prepared by general procedure 4.4 from propiolic acid (0.24 g,
mmol), DCC (0.72 g, 3.4 mmol) in toluene (10 mL, than washing
th 10 mL) and 19 (0.68 g, 3.4 mmol) in toluene (50 mL). Stirring
80 C for 2 h. Column chromatography gave 23 (445 mg, 58%) as
llow crystals. Mp: 168.5–170.5 C; 1H NMR (Me2SO-d6,
0 MHz) d (ppm): 3.64 (1H, s, C„CH), 7.53–7.61 (2H, m, H-70,
80), 7.69 (1H, t, J = 7.2 Hz, J = 7.9, H-30), 7.91 (1H, d, J = 8.3 Hz,
20), 8.03 (1H, d, J = 8.3 Hz, H-40), 8.17 (1H, d, J = 7.2 Hz, H-60),
0 (1H, d, J = 8.6 Hz, H-90). 13C NMR (Me2SO-d6 90 MHz) d
pm): 67.7 C„CH), 86.1 (C„CH), 119.4 (C-100), 124.7 (C-20),
5.7 (C-70), 126.8 (C-80), 128.4 (C-30), 128.7 (C-40), 128.8 (C-60),
9.7 (C-50), 133.2 (C-90), 133.7 (C-10), 149.1 (C-2), 165.0 (C-5).
al. Calcd for C14H8N2O (220.06): C, 76.35; H, 3.66; N, 12.72.
und: C, 76.43; H, 3.71; N, 12.79.
.4. 2-Ethynyl-5-(naphthalen-2-yl)-1,3,4-oxadiazole (24)
Prepared by general procedure 4.4 from propiolic acid (3.57 g,
mmol), DCC (5.25 g, 25.5 mmol) in toluene (50 mL, than wash-
g with 30 mL) and 20 (0.68 g, 3.4 mmol) in toluene (50 mL). Stir-
g at 80 C for 2 h. Column chromatography gave 24 (2.87 g, 51%)
white crystals. Mp: 168.5–170.5 C; 1H NMR (Me2SO-d6,
0 MHz) d (ppm): 5.4 (1H, s, C„CH), 7.67 (2H, m, H-70, H-80),
2–8.07 (4H, m, H-30, H-40, H-60, H-90), 8.64 (1H, s, H-10). 13C
R (Me2SO-d6 90 MHz) d (ppm): 67.4 C„CH), 90.3 (C„CH),
9.8 (C-20), 122.7 (C-30), 127.3 (C-40), 127.6 (C-60), 127.8 (C-90),
8.4 (C-10), 128.9 (C-70), 129.1 (C-80), 133.3 (C-50), 124.3 (C-100),
9.2 (C-2), 164.4 (C-5). Anal. Calcd for C14H8N2O (220.06): C,
.35; H, 3.66; N, 12.72; O. Found: C, 76.45; H, 3.69; N, 12.80.ease cite this article in press as: Kun, S.; et al. Carbohydr. Res. (2011), do.5. 2-(20,30,40,60-Tetra-O-benzoyl-b-D-glucopyranosyl)-5-
loromethyl-1,3,4-oxadiazole (25)
Tetrazole 17 (15.00 g, 23.13 mmol) was dissolved in dry toluene
00 mL), and chloroacetyl chloride (7.4 mL, 69.39 mmol) was
ded. The reaction mixture was heated at reﬂux. After 2 h TLC
:1 EtOAc–hexane) indicated completion of the transformation.
e solvent was evaporated under reduced pressure and the resi-
e was dissolved in CH2Cl2 (50 mL) then washed with cold satd
HCO3 solution (3  15 mL), brine (20 mL), and water (20 mL).
e combined organic phase was dried, ﬁltered, and evaporated
der reduced pressure to give 25 (15.54 g, 96%) as a yellow syrup.
e chromatographically uniform crude product was used for fur-
er transformations. Rf = 0.82 (1:1 EtOAc–hexane); 1H NMR
DCl3, 360 MHz) d (ppm): 8.08–7.80 (10H, m, Ph), 7.54–7.20
0H, m, Ph), 6.18 (1H, pt, J = 9.6, 9.5 Hz, H-20 or H-30 or H-40),
3 (1H, pt, J = 9.7 Hz, H-20 or H-30 or H-40), 5.90 (1H, pt,
9.7 Hz, H-20 or H-30 or H-40), 5.30 (1H, d, J10 ,20 = 10.0 Hz, H-10),
2–4.65 (3H, m, H-60a, CH2), 4.56 (1H, dd, J60a, 60b = 12.4 Hz, H-
), 4.43 (1H, m, J50 ,60a = 2.9 Hz, J50 ,60b = 5.2 Hz, J40 ,50 = 10.0 Hz, H-
. 13C NMR (CDCl3, 90 MHz) d (ppm): 165.9, 165.5, 164.9, 164.7
O), 163.5, 162.4 (oxadiazole), 133.4–127.9 (Ar), 76.8, 73.2, 71.5,
.3, 68.7 (C-10–C-50), 62.7 (C-60), 32.4 (CH2).
.6. 2-(20,30,40,60-Tetra-O-benzoyl-b-D-glucopyranosyl)-5-
idomethyl-1,3,4-oxadiazole (26)
Oxadiazole 25 (15.54 g, 22.29 mmol) was dissolved in dry DMF
0 mL), then NaN3 (5.80 g, 89.17 mmol) was added. The suspen-
n was heated and stirred at 50 C. After 2 h, TLC (1:3 EtOAc–hex-
e) indicated completion of the transformation. The solvent was
aporated under reduced pressure. The residue was diluted with
ter (400 mL) and extracted with Et2O (3  70 mL), the combined
ganic phase was washed with water (50 mL), dried, ﬁltered, and
ncentrated under reduced pressure to give 26 (13.60 g, 90%) as a
llow syrup. The chromatographically uniform crude product was
ed for further transformations. Rf = 0.81 (1:1 EtOAc–hexane); 1H
R (CDCl3, 360 MHz) d (ppm): 8.04–7.81 (10H, m, Ar), 7.58–7.25
0H, m, Ar), 6.10 (1H, pt, J = 10.7, 9.3 Hz, H-20 or H-30 or H-40), 5.84
H, pt, J = 10.5 Hz, H-20 or H-30 or H-40), 5.81 (1H, pt, J = 9.4 Hz, H-
or H-30 or H-40), 5.20 (1H, d, J10 ,20 = 10.7 Hz, H-10), 4.67 (1H, dd,
a,60b = 12.2 Hz, J50 ,60b = 2.8 Hz, H-60b), 4.63–4.50 (3H, m, H-60a,
2), 4.38–4.33 (1H, m, H-50). 13C NMR (CDCl3, 90 MHz) d (ppm):
6.0, 165.6, 165.1, 164.9 (CO), 163.1, 162.3 (oxadiazole), 133.6–
8.1 (Ar), 77.1, 73.2, 71.8, 70.5, 68.8 (C-10–C-50), 62.8 (C-60), 44.1
H2).
.7. 2-(Azidomethyl)-5-phenyl-1,3,4-oxadiazole (28)
A mixture of 2726 (6.00 g, 31 mmol), NaN3 (4.00 g, 93 mmol),
d 18-crown-6 (0.82 g, 10 mol %) in acetone (50 mL) was stirred
rt for 2 h. When the reaction was complete (TLC, 4:1 PhCH3–
OAc) the solids were ﬁltered off. The solvent was evaporated
d the residue was puriﬁed by ﬂash chromatography on alumin-
m oxide (CH2Cl2) to give 28 (5.72 g, 94%) as white crystals. Mp:
–68 C (lit.49 mp: 72–73 C); 1H NMR (Me2SO-d6, 360 MHz) d
pm): 3.91 (2H, s, CH2), 6.58–6.66 (3H, m, H-30, H-40, H-50), 6.99
H, dd, J = 8.6 Hz, 2.1 Hz, H-20, H-60). 13C NMR (Me2SO-d6
MHz) d (ppm): 43.5 CH2), 122.9 (C-10), 125.5 (C-20, C-60), 129.4
-30, C-50), 132.1 (C-40), 162.3 (C-2), 164.6 (C-5). Anal. Calcd for
H7N5O (201.07): C, 53.73; H, 3.51; N, 34.81. Found: C, 53.78; H,
2; N, 34.85.
. General procedures for the synthesis of 1,4-disubstituted-
-1,2,3-triazoles
.1. In CH2Cl2–water mixtures with organic azides
Equimolar amounts of an alkyne and an azide were dissolved in
2Cl2 (7 mL/mmol alkyne). Water (the same volume as that ofi:10.1016/j.carres.2011.03.004
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15 March 2011CH2Cl2), CuSO45H2O (5 mol %), L-ascorbic-acid (0.15 mol %) wer
added and the mixture was stirred at 50 C and monitored b
TLC (1:1 EtOAc–hexane). After disappearance of the starting mate
rials (aromatic azide: 2–3 h, glucosyl azide: overnight) the reactio
was diluted with water and CH2Cl2, the phases were separated, an
the aqueous layer was washed with CH2Cl2 (2  10 mL/mmol). Th
combined organic layer was dried, the solvent evaporated, and th
residue puriﬁed by column chromatography.
4.5.2. In CH2Cl2–water mixtures with organic azides prepared
in situ from boronic acids
A boronic acid (1 equiv) and NaN3 (1.2 equiv) were dissolved i
MeOH (5 mL/mmol of boronic acid). CuSO45H2O (0.1 equiv) wa
added and the mixture was stirred overnight. CH2Cl2 and wate
(10 mL of each/mmol of boronic acid), an alkyne (0.3 equiv) an
L-ascorbic acid (0.5 equiv) were added and the reaction mixtur
was heated to 50 C. After consumption of the alkyne (TLC 1:
EtOAc–hexane) the reaction was diluted with water and CH2Cl
the phases were separated and the aqueous layer was washed wit
CH2Cl2 (2  10 mL/mmol). The combined organic layer was dried
the solvent evaporated, and the residue puriﬁed by colum
chromatography.
4.5.3. In t-BuOH–water mixtures
Near equimolar amounts of an alkyne and an azide, catalyt
amount (1–4 mol %) of CuSO45H2O, Na-L-ascorbate, and TMED
were placed in a 1:2 mixture of t-BuOH and water. The reactio
mixture was stirred at the given temperature for the indicate
time. When TLC (4:1 PhCH3–EtOAc) indicated complete transfor
mation of the starting materials the precipitate was ﬁltered o
and washed with water and then with hexane. Further puriﬁcation
if necessary, was performed by ﬂash chromatography (4:1 PhCH3
EtOAc).
4.5.4. 2-(20,30,40,60-Tetra-O-benzoyl-b-D-glucopyranosyl)-5-(1-
phenyl-1,2,3-triazol-4-yl)-1,3,4-oxadiazole (29)
(i) Prepared by general procedure 4.8.1 from 21 (150 m
0.22 mmol) and PhN3 for 2 h. Column chromatography (3:
EtOAc–hexane) and crystallization from ethanol gave 29 (128 m
73%) as white crystals. Rf = 0.58 (1:1 EtOAc–hexane), mp: 137
140 C, [a]D = 194 (c 0.16, CHCl3), 1H NMR (CDCl3, 360 MHz)
(ppm): 8.65 (1H, s, triazole-H), 8.04–7.77 (10H, m, Ar), 7.58–7.2
(15H, m, Ar), 6.14 (1H, t, J = 9.3 Hz, H-20 or H-30 or H-40), 6.0
(1H, pt, J = 9.3, 10.5 Hz, H-20 or H-30 or H-40), 5.89 (1H, pt, J = 9.3
10.5 Hz, H-20 or H-30 or H-40), 5.33 (1H, d, J10 ,20 = 9.3 Hz, H-10
4.69 (1H, dd, J60a,60b = 11.9 Hz, J50 ,60a <1 Hz H-60a), 4.56 (1H, dd
J60a,60b = 11.9 Hz, J50 ,60b = 5.3 Hz, H-60b), 4.42 (1H, ddd, J <1 Hz, H
50). 13C NMR (CDCl3, 90 MHz) d (ppm): 166.1, 165.7, 165.1, 164.
(CO), 161.3, 159.2 (oxadiazole), 136.1–120.8 (Ar, triazole-C, tria
zole-CH), 77.1, 73.5, 71.8, 70.5, 69.00 (C-10–C-50), 63.1 (C-60). Ana
Calcd for C44H35N5O10 (791.76): C, 66.75; H, 4.20; N, 8.85; O, 20.21
Found: C, 66.82; H, 4.15; N, 8.91.
(ii) Prepared by general procedure 4.8.2 from PhN3 (prepare
in situ from phenylboronic acid (27 mg, 0.22 mmol)) and 21 fo
2 h. Column chromatography (3:7 EtOAc–hexane) and crystalliza
tion from ethanol gave 29 (40 mg, 68%) as white crystals.
4.5.5. 2-(20,30,40,60-Tetra-O-benzoyl-b-D-glucopyranosyl)-5-(1-
phenyl-1,2,3-triazol-4-yl)-1,3,4-oxadiazole (29)
(i) Prepared by general procedure 4.8.1 from 21 (150 m
0.22 mmol) and PhN3 for 2 h. Column chromatography (3:
EtOAc–hexane) and crystallization from ethanol gave 29 (128 m
73%) as white crystals. Rf = 0.58 (1:1 EtOAc–hexane), mp: 137
140 C, [a]D = 194 (c 0.16, CHCl3), 1H NMR (CDCl3, 360 MHz)
(ppm): 8.65 (1H, s, triazole-H), 8.04–7.77 (10H, m, Ar), 7.58–7.2
(15H, m, Ar), 6.14 (1H, t, J = 9.3 Hz, H-20 or H-30 or H-40), 6.0Please cite this article in press as: Kun, S.; et al. Carbohydr. Res. (201(1H, pt, J = 9.3, 10.5 Hz, H-20 or H-30 or H-40), 5.89 (1H, pt, J = 9.3
10.5 Hz, H-20 or H-30 or H-40), 5.33 (1H, d, J10 ,20 = 9.3 Hz, H-10
4.69 (1H, dd, J60a,60b = 11.9 Hz, J50 ,60a <1 Hz H-60a), 4.56 (1H, dd
J60a,60b = 11.9 Hz, J50 ,60b = 5.3 Hz, H-60b), 4.42 (1H, ddd, J <1 Hz, H
50). 13C NMR (CDCl3, 90 MHz) d (ppm): 166.1, 165.7, 165.1, 164.
(CO), 161.3, 159.2 (oxadiazole), 136.1–120.8 (Ar, triazole-C, tria
zole-CH), 77.1, 73.5, 71.8, 70.5, 69.00 (C-10–C-50), 63.1 (C-60). Ana
Calcd for C44H35N5O10 (791.76): C, 66.75; H, 4.20; N, 8.85; O, 20.21
Found: C, 66.82; H, 4.15; N, 8.91.
4.5.6. 2-Phenyl-5-(1-phenyl-1H-1,2,3-triazol-4-yl)-1,3,4-
oxadiazole (33)
Prepared by general procedure 4.8.3 from 22 (171 mg, 1 mmo
and PhN3 (100 mg, 0.84 mmol) in the presence of CuSO45H2
(8 mg, 0.034 mmol), Na-L-ascorbate (27 mg, 0.13 mmol), and TME
DA (10 lL, 0.07 mmol) in 6 mL solvent mixture at rt for 24 h to giv
33 (197 mg, 81%) as pale yellow crystals. Mp: 201–202 C; 1H NM
(Me2SO-d6, 360 MHz) d (ppm): 7.56–7.63 (6H, m, H-300-500, H-300
5000), 7.84 (2H, d, J = 7.7 Hz, H-200, H-600), 8.22 (2H, d, J = 7.9 H-20
H-6000), 8.76 (1H, s, H-50). 13C NMR (Me2SO-d6, 90 MHz) d (ppm
119.1 (C-3000, C-5000), 121.6 (C-1000), 125.3 C-2000, C-6000), 128.0 (C-50
128.1 (C-300, C-500), 128.6 (C-200, C-600, C-4000), 130.8 (C-400), 132.2 (C
100), 134.6 (C-40), 156.3 (C-5), 162.4 (C-2). Anal. Calcd fo
C16H11N5O (289.10): C, 66.43; H, 3.83; N, 24.21. Found: C, 66.51
H, 3.91; N, 24.29.
4.5.7. 2-(4-(5-Phenyl-1,3,4-oxadiazol-2-yl)-1H-1,2,3-triazol-1-
yl)ethanol (34)
Prepared by general procedure 4.8.3 from 22 (235 m
1.38 mmol) and 2-azidoethanol (100 mg, 1.15 mmol) in the pres
ence of CuSO45H2O (12 mg, 0.046 mmol), Na-L-ascorbate (36 m
0.18 mmol), and TMEDA (14 lL, 0.10 mmol) in 10 mL solvent mix
ture at rt for 24 h to give 34 (270 mg, 76%) as pale yellow crystal
Mp: 176–178 C; 1H NMR (Me2SO-d6, 360 MHz) d (ppm): 3.88 (2H
d, J = 4.0 Hz, N-CH2), 4.57 (2H, br s, CH2–OH), 5.13 (1H, s, OH), 7.6
(3H, br s, H-300, H-400, H-500), 8.11 (2H, d, J = 4.7 Hz, H-200, H-600), 9.0
(1H, s, H-50). 13C NMR (Me2SO-d6, 90 MHz) d (ppm): 52.7 N-CH2
59.5 (CH2–OH), 123.0 (C-100), 126.5 (C-200, C-600), 126.8 (C-50
129.4 (C-300, C-500), 132.1 (C-100), 132.3 (C-40), 158.1 (C-5), 163.
(C-2). Anal. Calcd for C12H11N5O2 (257.09): C, 56.03; H, 4.31; N
27.22. Found: C, 56.12; H, 4.35; N, 27.28.
4.5.8. 2-Phenyl-5-[1-(20,30,40,60-tetra-O-acetyl-b-D-
glucopyranosyl)-1,2,3-triazol-4-yl]-1,3,4-oxadiazole (35)
Prepared by general procedure 4.8.1 from 2,3,4,6-tetra-O-ace
yl-b-D-glucopyranosyl-azide31,32 (300 mg, 0.80 mmol) and 22 fo
28 h. Column chromatography (1:1 EtOAc–hexane) gave 3
(360 mg, 87%) as a white amorphous solid. Rf = 0.24 (1:1 EtOAc
hexane), [a]D = 139 (c 0.17, CHCl3); 1H NMR (CDCl3, 360 MHz)
(ppm): 8.68 (1H, s, triazole-H), 8.19 (2H, d, J = 6.6 Hz, Ar), 7.58
7.52 (3H, m, Ar), 6.03 (1H, d, J10 ,20 = 8.8 Hz, H-10), 5.52–5.50 (2H
m, 2 of H-20 or H-30 or H-40), 5.32 (1H, pt, J = 9.7, 9.5 Hz, H-20 o
H-30 or H-40), 4.35 (1H, dd, J50 ,60a = 4.9 Hz, J60a,60b = 12.6 Hz, H-60a
4.21 (1H, dd, J50 ,60b 1.3 Hz, J60a,60b = 12.6 Hz, H-60b) 4.10 (1H, ddd
J50 ,60b 1.3 Hz, J50 ,60a = 4.9 Hz, J50 ,40 = 9.7 Hz, H-50), 2.11, 2.10, 2.05
1.92 (12H, 4s, CH3). 13C NMR (CDCl3, 90 MHz) d (ppm): 170.4
169.8, 169.3, 168.9 (CO), 164.8, 157.6 (oxadiazole), 134.6 (tria
zole-C), 132.0, 129.1, 127.2, 123.3 (Ar), 123.2 (triazole-CH), 86.
75.4, 72.3, 70.5, 67.5 (C-10–C-50), 61.4 (C-60), 20.6, 20.5, 20.4, 20.
(CH3). Anal. Calcd for C24H25N5O10 (543.16): C, 53.04; H, 4.64; N
12.89; O, 29.44. Found: C, 53.00; H, 4.61; N, 12.81.
4.5.9. 2-Phenyl-5-[1-(b-D-glucopyranosyl)-1,2,3-triazol-4-yl]-
1,3,4-oxadiazole (36)
Prepared by general procedure 4.2 from 35 (146 m
0.27 mmol) for 17 h. Filtration of the reaction mixture gave 31), doi:10.1016/j.carres.2011.03.004
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Pl00 mg, 99%) as a white solid. Rf = 0.60 (7:3 CHCl3–MeOH),
]D = 23 (c 0.19, Me2SO); 1H NMR (Me2SO-d6, 360 MHz) d
pm): 9.32 (1H, s, triazole-CH), 8.09 (m, 2H, Ar), 7.64 (m, 3H,
), 5.69 (1H, d, J10 ,20 = 7.9 Hz, H-10), 3.87 (1H, pt, J = 7.9, 9.3 Hz,
20 or H-30 or H-40), 3.72 (1H, dd, J60a,60b = 10.6, J50 ,60a <1 Hz, H-
), 3.48 (3H, m, H-20 or H-30 or H-40, H-50, H-60b), 3.30 (1H, t,
7.9 Hz, H-20 or H-30 or H-40). 13C NMR (Me2SO-d6, 90 MHz) d
pm): 163.7, 157.9 (oxadiazole), 132.7 (triazole-C), 132.6, 132.1,
9.4, 126.6, 123.1 (Ar, triazole-CH), 88.11, 80.12, 76.83, 72.27,
.50 (C-10–C-50), 60.73 (C-60). Anal. Calcd for C16H17N5O6
75.12): C, 51.20; H, 4.57; N, 18.66; O, 25.58. Found: C, 51.25;
4.55; N, 18.68.
.10. 2-(Naphthalen-1-yl)-5-(1-phenyl-1H-1,2,3-triazol-4-yl)-
,4-oxadiazole (37)
Prepared by general procedure 4.8.3 from 23 (185 mg,
4 mmol) and PhN3 (100 mg, 0.84 mmol) in the presence of Cu-
45H2O (8 mg, 0.034 mmol), Na-L-ascorbate (27 mg, 0.13 mmol),
d TMEDA (10 lL, 0.07 mmol) in 10 mL solvent mixture at 50 C
r 168 h to give 37 (135 mg, 48%) as orange crystals. Mp: 186–
8 C; 1H NMR (Me2SO-d6, 360 MHz) d (ppm): 7.50–7.61 (5H,
, H-200–H-600), 7.69 (1H, t, J = 8.3 Hz, J = 7,2 Hz, H-3000), 7.82 (2H,
J = 7.9 Hz, H-7000, H-8000), 7.92 (1H, d, J = 7.9 Hz, H-2000), 8.04 (1H,
J = 8.3 Hz, H-4000), 8.37 (1H, d, J = 7.2 Hz, H-6000), 8.79 (1H, s, H-
, 9.32 (1H, d, J = 8.6 Hz, H-9000-H). 13C NMR (Me2SO-d6, 90 MHz)
(ppm): 119.8 C-100), 120.8 (C-300–C-500), 122.6 (C-50), 124.9 –
2.9 (C-200,C-600, C-2000–C-4000, C-6000–C-9000) 132.8 (C-5000, C-10000),
3.7(C-1000), 134.5 (C-100), 136.2 (C-40), 157.4 (C-2), 164.7 (C-5).
al. Calcd for C20H13N5O (339.11): C, 70.79; H, 3.86; N, 20.64.
und: C, 70.85; H, 3.80; N.
.11. 2-{4-[5-(Naphthalen-1-yl)-1,3,4-oxadiazol-2-yl]-1H-
,3-triazol-1-yl}ethanol (38)
Prepared by general procedure 4.8.3 from 23 (202 mg,
2 mmol) and 2-azidoethanol (80 mg, 0.92 mmol) in the pres-
ce of CuSO45H2O (9 mg, 0.037 mmol), Na-L-ascorbate (29 mg,
5 mmol), and TMEDA (14 lL, 0.10 mmol) in 10 mL solvent mix-
re at rt for 29 h then then at 50 C for 16 h to give 34 (243 mg,
%) as white crystals. Mp: 198–199 C; 1H NMR (Me2SO-d6,
0 MHz) d (ppm): 3.90 (2H, d, J = 4,7 Hz, N-CH2), 4.59 (2H, t,
4,7 Hz, CH2–OH), 5.17 (1H, t, J = 5.0, OH), 7.68–7.81 (3H, m, H-
, H-700, H-800), 8.13 (1H, d, J = 7.6 Hz, H-200), 8.26 (1H, d,
8,3 Hz, H-400), 8.33 (1H, d, J = 7.2 Hz, H-600), 9.07 (1H, s, H-50),
6 (1H, d, J = 8.3 Hz, H-900). 13C NMR (Me2SO-d6, 90 MHz) d
pm): 52.7 N-CH2), 59.5 (CH2–OH), 119.3 (C-100), 125.3–132.7 (C-
C-200–C-400, C-600–C-800) 132.7 (C-1000), 133.1 (C-900), 133.8 (C-40),
7.6 (C-5), 163.4 (C-2). Anal. Calcd for C16H13N5O2 (307.11): C,
.53; H, 4.26; N, 22.79. Found: C, 62.41; H, 4.24; N, 22.72.
.12. 2-(Naphthalen-1-yl)-5-[1-(20,30,40,60-tetra-O-acetyl-b-D-
copyranosyl)-1,2,3-triazol-4-yl]-1,3,4-oxadiazole (39)
Prepared by general procedure 4.8.1 from 2,3,4,6-tetra-O-acet-
b-D-glucopyranosyl-azide31,32 (300 mg, 0.80 mmol) and 23 for
h. Crystallization from EtOH gave 39 (365 mg, 77%) as white
stals. Rf = 0.38 (1:1 EtOAc–hexane), mp: 181–182 C,
]D = 140 (c 0.21, CHCl3); 1H NMR (CDCl3, 360 MHz) d (ppm):
9 (1H, d, J = 8.6 Hz, Ar), 8.76 (1H, s, triazole-CH), 8.31 (1H, d,
7.2 Hz, Ar), 8.02 (1H, d, J = 8.2 Hz, Ar), 7.91 (1H, d, J = 8.1 Hz,
), 7.70 (1H, pt, J = 7.8, 7.5 Hz Ar), 7.58 (2H, m, Ar), 6.10 (1H, d,
,20 = 7.9 Hz, H-10), 5.59–5.50 (2H, m, 2 of H-20 or H-30 or H-40),
5 (1H, pt, J = 9.6, 9.4 Hz, H-20 or H-30 or H-40), 4.37 (1H, dd,
,60a = 5.0 Hz, J60a,60b = 12.7 Hz, H-60a), 4.22 (1H, dd, J60a,60b = 12.6 Hz,
,60b = 1.6 Hz, H-60b), 4.14 (1H, ddd, J50 ,60b = 1.6 Hz, J50 ,60a = 4.9 Hz,
,50 = 9.9 Hz, H-50), 2.11, 2.10, 2.06, 1.94 (12H, 4s, CH3). 13C NMR
DCl3, 90 MHz) d (ppm): 170.4, 169.8, 169.2, 168.8 (CO), 164.6,
7.1 (oxadiazole), 134.6, 133.7, 132.8, 129.9, 128.7, 128.6, 128.2,ease cite this article in press as: Kun, S.; et al. Carbohydr. Res. (2011), do6.3, 126.0, 124.8, 123.5, 119.7 (Ar, triazole-C, triazole-CH),
.9, 75.2, 72.2, 70.5, 67.5 (C-10–C-50), 61.3 (C-60), 20.6, 20.5, 20.4,
.0 (CH3). Anal. Calcd for C28H27N5O10 (593.18): C, 56.66; H,
9; N, 11.80; O, 26.96. Found: C, 56.58; H, 4.53; N, 11.77.
.13. 2-(Naphthalen-1-yl)-5-[1-(b-D-glucopyranosyl)-1,2,3-
azol-4-yl]-1,3,4-oxadiazole (40)
Prepared by general procedure 4.2 from 39 (202 mg,
4 mmol) for 4 h. Filtration of the reaction mixture gave 40
42 mg, 98%) as a white amorphous solid. Rf = 0.50 (7:3 CHCl3–
eOH), [a]D = 8 (c 0.18, Me2SO); 1H NMR (Me2SO-d6, 360 MHz)
ppm): 9.42 (1H, s, triazole-CH), 9.16 (1H, d, J = 8.6 Hz, Ar), 8.33
H, d, J = 7.3 Hz, Ar), 8.24 (1H, d, J = 8.2 Hz, Ar), 8.11 (1H, d,
8.1 Hz, Ar), 7.80–7.67 (3H, m, Ar), 5.75 (1H, d, J10 ,20 = 9.2 Hz, H-
, 3.91 (1H, pt, J = 9.0, 9.1 Hz H-20 or H-30 or H-40), 3.75 (1H, dd,
a,60b = 10.7 Hz, J50 ,60a <0 Hz, H-60a), 3.57–3.44 (3H, m, H-20 or H-
or H-40, H-50, H-60b), 3.32 (1H, pt, J = 9.0, 8.9 Hz, H-20 or H-30 or
40). 13C NMR (Me2SO-d6, 90 MHz) d (ppm): 163.6, 157.5 (oxadi-
ole), 133.4, 132.8, 132.7, 129.1, 128.9, 128.8, 128.3, 126.9,
6.0, 125.4, 125.3, 119.4 (Ar, triazole-C, triazole-CH), 87.9, 80.1,
.6, 72.2, 69.4 (C-10–C-50), 60.7 (C-60). Anal. Calcd for
0H19N5O6 (425.13): C, 56.47; H, 4.50; N, 16.46; O, 22.57. Found:
56.46; H, 4.54; N, 16.52.
.14. 2-(Naphthalen-2-yl)-5-(1-phenyl-1H-1,2,3-triazol-4-yl)-
,4-oxadiazole (41)
Prepared by general procedure 4.8.3 from 24 (185 mg,
4 mmol) and PhN3 (100 mg, 0.84 mmol) in the presence of Cu-
45H2O (8 mg, 0.034 mmol), Na-L-ascorbate (27 mg, 0.13 mmol),
d TMEDA (10 lL, 0.07 mmol) in 10 mL solvent mixture at 50 C
r 168 h to give 41 (127 mg, 45%) as pale yellow crystals. Mp:
3–225 C; 1H NMR (Me2SO-d6, 360 MHz) d (ppm): 7.59 (1H, t,
6.5 Hz, J = 6,8 Hz, H-400), 7.60–7.71 (4H, m, H-300, H-500, H-6000, H-
0), 8.06–8.08 (3H, m, H-2000, H-200, H-600), 8.18–8.21 (3H, m, H-3000,
7000, H-8000), 8.74 (1H, s, H-9000), 9.83 (1H, s, H-50). 13C NMR
e2SO-d6, 90 MHz) d (ppm): 120.5 C-100), 120.8 (C-200, C-600),
3.2 (C-50), 127.1–130.0 (C-300–C-500, C-2000, C-3000, C-5000–C-8000, C-
000), 132.8 (C-1000), 134.6 (C-9000), 134.8 (C-4000), 136.2 (C-40), 157.9
-5), 165.0 (C-2). Anal. Calcd for C20H13N5O (339.11): C, 70.79;
3.86; N, 20.64. Found: C, 70.87; H, 3.81; N, 20.65.
.15. 2-{4-[5-(Naphthalen-2-yl)-1,3,4-oxadiazol-2-yl]-1H-
,3-triazol-1-yl}ethanol (42)
Prepared by general procedure 4.8.3 from 24 (303 mg,
8 mmol) and 2-azidoethanol (100 mg, 1.15 mmol) in the pres-
ce of CuSO45H2O (12 mg, 0.046 mmol), Na-L-ascorbate (36 mg,
8 mmol), and TMEDA (14 lL, 0.10 mmol) in 10 mL solvent mix-
re at rt for 5 d then at 50 C for 1 d to give 42 (423 mg, 76%) as
le yellow crystals. Mp: 195–198 C; 1H NMR (Me2SO-d6,
0 MHz) d (ppm): 3.90 (2H, d, J = 4,0 Hz, N-CH2), 4.59 (2H, br s,
2–OH), 5.16 (1H, s, OH), 7.68 (2H, br s, H-600, H-700), 8.06 (1H,
J = 5.4 Hz, H-200), 8.17 (3H, br s, H-300, H-500, H-800), 8.72 (1H, s,
1000), 9.04 (1H, s, H-50). 13C NMR (Me2SO-d6, 90 MHz) d (ppm):
.7 N-CH2), 59.5 (CH2–OH), 120.3 (C-100), 122.7 (C-50), 127.0–
9.2 (C-200, C-300, C-500–C-800, C-1000), 132.3 (C-400), 132.4 (C-900),
4.2 (C-40), 158.1 (C-5), 163.7 (C-2). Anal. Calcd for C16H13N5O2
07.11): C, 62.53; H, 4.26; N, 22.79. Found: C, 62.45; H, 4.27; N,
.82.
.16. 2-(Naphthalen-2-yl)-5-[1-(20,30,40,60-tetra-O-acetyl-b-D-
copyranosyl)-1,2,3-triazol-4-yl]-1,3,4-oxadiazole (43)
Prepared by general procedure 4.8.1 from 2,3,4,6-tetra-O-acet-
b-D-glucopyranosyl-azide31,32 (300 mg, 0.80 mmol) and 24 for
h. Column chromatography (1:2 EtOAc–hexane) gave 43
55 mg, 74%) as white crystals. Rf = 0.38 (6:4 EtOAc–hexane),
p: 210–214 C, [a]D = 134 (c 0.22, CHCl3); 1H NMR (CDCl3,i:10.1016/j.carres.2011.03.004
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15 March 2011360 MHz) d (ppm): 8.75 (1H, s, Ar), 8.68 (1H, s, Ar), 8.23 (1H, d
J = 1.6, 8.6 Hz, Ar), 7.96 (2H, m, Ar), 7.90 (1H, m, Ar), 7.58 (2H, m
Ar), 6.06 (1H, d, J10 ,20 = 7.9 Hz, H-10), 5.53 (2H, m, 2 of H-20 or H-3
or H-40), 5.35 (1H, t, J = 9.3 Hz, H-20 or H-30 or H-40), 4.37 (1H, dd
J50 ,60a = 5.3 Hz, J60a,60b = 13.2 Hz, H-60a), 4.22 (1H, dd, J60a,60b = 13.2 H
J50 ,60b = 1.9 Hz, H-60b), 4.12 (1H, ddd, J40 ,50 = 9.3 Hz, J50 ,60a = 5.
Hz5060b = 1.9 Hz, H-50), 2.11, 2.10, 2.05, 1.93 (12H, 4s, CH3). 13
NMR (CDCl3, 90 MHz) d (ppm): 170.4, 169.8, 169.3, 168.9 (CO
164.9, 157.6 (oxadiazole), 137.8, 134.6, 132.7, 129.0, 128.8, 128.
127.9, 127.8, 127.1, 123.5, 123.2, 120.5 (Ar, triazole-C, triazole
CH), 86.0, 75.4, 72.3, 70.5, 67.5 (C-10–C-50), 61.4 (C-60), 20.6, 20.5
20.4, 20.1 (CH3). Anal. Calcd for: C28H27N5O10 (593.18): C, 56.66
H, 4.59; N, 11.80; O, 26.96. Found: C, 56.61; H, 4.50; N, 11.74.
4.5.17. 2-(Naphthalen-2-yl)-5-[(1-b-D-glucopyranosyl)-1,2,3-
triazol-4-yl]-1,3,4-oxadiazole (44)
Prepared by general procedure 4.2 from 43 (182 m
0.31 mmol) for 2 h. Filtration of the reaction mixture gave 4
(128 mg, 98%) as a white amorphous solid. Rf = 0.60 (7:3 CHCl3
MeOH), [a]D = 11 (c 0.20, Me2SO); 1H NMR (Me2SO-d
360 MHz) d (ppm): 9.43 (1H, s, triazole-H), 8.76 (1H, s, Ar), 8.2
(3H, m, Ar), 8.10 (1H, m, Ar), 7.11 (2H, m, Ar), 5.78 (1H, d
J10 ,20 = 9.3 Hz, H-10), 3.93 (1H, t, J = 9.3 Hz, H-20 or H-30 or H-40
3.79 (1H, dd, J60a,60b = 11.9, J50 ,60a <1 Hz), 3.60–3.47 (3H, m, H-20 o
H-30 or H-40, H-50, H-60b), 3.35 (1H, t, J = 9.3 Hz, H-20 or H-30 o
H-40). 13C NMR (Me2SO-d6, 90 MHz) d (ppm): 163.9, 157.9 (oxad
azole), 134.2, 132.7, 132.4, 129.3, 128.9, 128.3, 127.9, 127.4
127.1, 125.9, 122.8, 120.4 (Ar, triazole-C, triazole-CH), 87.9, 80.1
76.6, 72.2, 69.4 (C-10–C-50), 60.7 (C-60). Anal. Calcd fo
C20H19N5O6 (425.13): C, 56.47; H, 4.50; N, 16.46; O, 22.57. Found
C, 56.50; H, 4.54; N, 16.53.
4.5.18. 2-(b-D-Glucopyranosyl)-5-(1-phenyl-1,2,3-triazol-4-yl)-
1,3,4-oxadiazole (45)
Prepared by general procedure 4.2 from 29 (249 m
0.31 mmol) for 2 h. Column chromatography (9:1 CHCl3–MeOH
gave 45 (100 mg, 85%) as white crystals. Rf = 0.39 (8:2 CHCl3
MeOH), mp: 219–221 C, [a]D = +28 (c 0.22, Me2SO); 1H NM
(Me2SO-d6, 360 MHz) d (ppm): 9.78 (1H, s, triazole-H), 8.05 (2H
d, J = 7.9 Hz, Ar), 7.66 (2H, pt, J = 7.9, 6.6 Hz, Ar), 7.57 (1H, p
J = 6.6, 7.9 Hz, Ar), 5.45 (1H, d, J = 5.3 Hz, OH), 5.22 (1H, d
J = 4.0 Hz, OH), 5.14 (1H, d, J = 4.0 Hz, OH), 4.66 (1H, d, J = 5.3 H
OH), 4.61 (1H, d, J10 ,20 = 10.6 Hz, H-10), 3.73–3.18 (6H, m, H-20, H
30, H-40, H-50, H-60a, H-60b). 13C NMR (Me2SO-d6, 90 MHz)
(ppm): 163.7, 158.1 (oxadiazole), 133.4 (triazole-C), 130.2, 129.9
124.5 (Ar), 120.5 (triazole-CH), 81.8, 77.2, 72.6, 71.8, 69.
(C-10–C-60), 60.9 (C-60). Anal. Calcd for C16H17N5O6 (375.12): C
51.20; H, 4.57; N, 18.66; O, 25.58. Found: C, 51.15; H, 4.53; N
18.59.
4.5.19. 2-(b-D-Glucopyranosyl)-5-[1-(naphthalen-1-yl)-1,2,3-
triazol-4-yl]-1,3,4-oxadiazole (46)
Prepared by general procedure 4.2 from 30 (350 m
0.42 mmol) for 3 h. Column chromatography (9:1 CHCl3–MeOH
gave 46 (161 mg, 91%) as a pale yellow amorphous solid
Rf = 0.35 (8:2 CHCl3–MeOH), [a]D = +19 (c 0.17, MeOH); 1H NM
(CD3OD, 360 MHz) d (ppm): 9.12 (1H, s, triazole-H), 8.12 (1H, d
J = 8.0 Hz, Ar), 8.02 (1H, d, J = 7.8 Hz, Ar), 7.71–7.55 (5H, m, Ar
4.72 (1H, d, J10 ,20 = 10.6 Hz, H-10), 3.94–3.85 (2H, m, H-60a, H-20 o
H-30 or H-40), 3.66–3.48 (4H, m, 2 of H-20 or H-30 or H-40, H-50, H
60b). 13C NMR (CD3OD, 90 MHz) d (ppm): 165.6, 160.2 (oxadiazole
135.6, 134.5, 133.9, 132.3, 129.5, 129.3, 128.5, 126.4, 126.2, 125.2
123.1, 122.7 (Ar, triazole-C, triazole-CH), 82.5, 79.1, 74.5, 73.4, 71.
(C10–C-50), 62.7 (C-60). Anal. Calcd for C20H19N5O6 (425.13): C
56.47; H, 4.50; N, 16.46; O, 22.57. Found: C, 56.42; H, 4.48; N
16.42.Please cite this article in press as: Kun, S.; et al. Carbohydr. Res. (2014.5.20. 2-(b-D-Glucopyranosyl)-5-[1-(naphthalen-2-yl)-1,2,3-
triazol-4-yl]-1,3,4-oxadiazole (47)
Prepared by general procedure 4.2 from 31 (220 m
0.26 mmol) for 3 h. Column chromatography (9:1 CHCl3–MeOH
gave 47 (88 mg, 79%) as a greenish amorphous solid. Rf = 0.3
(8:2 CHCl3–MeOH), [a]D = +8 (c 0.14, Me2SO); 1H NMR (Me2SO
d6, 360 MHz) d (ppm): 9.90 (1H, s, triazole-H), 8.68 (1H, s, Ar
8.22 (2H, m, Ar) 8.09 (2H, t, J = 7.9 Hz, Ar), 7.66 (2H, m, Ar), 5.5
(1H, d, J = 6.6 Hz, OH), 5.29 (1H, d, J = 4.0 Hz, OH), 5.20 (1H, d
J = 5.3 Hz, OH), 4.70 (1H, t, J = 5.3 Hz, OH), 4.65 (1H, d
J10 ,20 = 10.6 Hz, H-10), 3.79–3.66 (2H, m, H-60a, H-60b), 3.54–3.2
(4H, m, H-20, H-30, H-40, H-50). 13C NMR (Me2SO-d6, 90 MHz)
(ppm): 163.8, 158.1 (oxadiazole), 133.5, 133.3, 132.7, 132.6
129.9, 128.3, 127.8, 127.6, 127.3, 124.6, 118.6, 118.5 (Ar, triazole
C, triazole-CH), 81.8, 77.3, 72.6, 71.8, 69.9 (C-10–C-50), 60.9 (C-60
Anal. Calcd for C20H19N5O6 (425.13): C, 56.47; H, 4.50; N, 16.46
O, 22.57. Found: C, 56.43; H, 4.50; N, 16.47.
4.5.21. 2-(b-D-Glucopyranosyl)-5-[1-(b-D-glucopyranosyl)-1,2,3-
triazol-4-yl]-1,3,4-oxadiazole (48)
Prepared by general procedure 4.2 from 32 (240 m
0.23 mmol) for 16 h. Column chromatography (6:4 CHCl3–MeOH
gave 48 (98 mg, 93%) as a colourless oil. Rf = 0.31 (4:
CHCl3–MeOH), [a]D = +24 (c 0.20, MeOH); 1H NMR (CD3OD
360 MHz) d (ppm): 9.04 (1H, s, triazole-H), 5.78 (1H, d
J10 ,20 = 7.9 Hz, H-10), 4.70 (1H, d, J = 9.3 Hz, H-100), 4.01–3.47 (12H
m, H-20, H-30, H-40, H-50, H-60a, H-60b, H-200, H-300, H-400, H-5
H-600a, H-600b). 13C NMR (CD3OD, 90 MHz) d (ppm): 165.5, 160.
(oxadiazole), 134.3 (triazole-C), 126.9 (triazole-CH), 89.8, 81.2
78.7, 78.2, 74.4, 74.1, 73.4, 71.2, 70.7 (C-10–C-50, C-100-C-500
62.7, 62.3 (C-60, C-600). Anal. Calcd for C16H23N5O11 (461.14): C
41.56; H, 5.02; N, 15.18; O, 38.14. Found: C, 41.64; H, 5.01; N
15.18.
4.5.22. 2-(200,300,400,600-Tetra-O-benzoyl-b-D-glucopyranosyl)-5-(4
phenyl-10,20,30-triazole-10-ylmethyl)-1,3,4-oxadiazole (49)
Oxadiazole 26 (100 mg, 0.14 mmol) was dissolved in CH2C
(2 mL) and water (2 mL), phenylacetylene (14 lL, 0.14 mmol), cop
per triﬂate (2 mg, 5.2  103 mmol) and copper dust (0.3 m
4.7  103 mmol) was added. The reaction mixture was heated a
40 C. After 24 h TLC (1:1 EtOAc–hexane) indicated completion o
the transformation. The reaction mixture was diluted with CH2C
(20 mL), the phases were separated, and the organic phase wa
washed with cold satd NaHCO3 solution (3  10 mL), wate
(10 mL), dried, ﬁltered, and concentrated under reduced pressur
The crude product was puriﬁed by column chromatography (1:
EtOAc–hexane) to give 49 (56 mg, 70%, conversion 70%) as a co
ourless syrup. Rf = 0.35 (1:1 EtOAc–hexane); [a]D = 50.4 (c 0.22
CHCl3); 1H NMR (CDCl3, 360 MHz) d (ppm): 8.05 (1H, s, triazole
CH), 8.02–7.72 (10H, m, Ar), 7.56–7.23 (15H, m, Ar), 6.06 (1H, p
J = 9.6 Hz, H-200 or H-300 or H-400), 5.89 (2H, bs, CH2), 5.82 (1H, p
J = 9.9 Hz, H-200 or H-300 or H-400), 5.74 (1H, pt, J = 10.0, 9.8 Hz, H
200 or H-300 or H-400), 5.71 (1H, d, J100 ,200 = 10.1 Hz, H-100), 4.65 (1H
dd, J600a,600b = 12.5 Hz, J500 ,600a = 1.7 Hz, H-600a), 4.50 (1H, dd
J500 ,600b = 5.3 Hz, H-600b), 4.36–4.31 (1H, m, H-500). 13C NMR (CDCl
360 MHz) d (ppm): 166.0, 165.6, 165.1, 165.0 (CO), 162.9, 161.
(oxadiazole), 148.7 (triazole-C), 133.7–125.8 (Ar), 120.1 (triazole
CH), 77.2, 73.0, 71.8, 70.7, 68.7 (C-200-C-500), 62.8 (C-600), 44.
(CH2). Anal. Calcd for C45H35N5O10 (805.79): C, 67.07; H, 4.38; N
8.69. Found: C, 66.92; H, 4.27; N, 9.36.
4.5.23. 2-(200,300,400,600-Tetra-O-benzoyl-b-D-glucopyranosyl)-5-(4
ethoxycarbonyl-10,20,30-triazole-10-ylmethyl)-1,3,4-oxadiazole
(50)
Prepared by general procedure 4.8.1 from 26 (150 m
0.21 mmol). Column chromatography (1:1 EtOAc–hexane) gav1), doi:10.1016/j.carres.2011.03.004
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Pl(107 mg, 82%, conversion 77%) as a colourless syrup. Rf = 0.22
:1 EtOAc–hexane); [a]D = +57.1 (c 0.21, CHCl3); 1H NMR (CDCl3,
0 MHz) d (ppm): 8.42 (1H, s, triazole-CH), 8.03–7.78 (8H, m,
), 7.58–7.25 (12H, m, Ar), 6.11 (1H, pt, J = 10.0, 9.5 Hz, H-200 or
300 or H-400), 5.91 (2H, br s, CH2), 5.82 (1H, pt, J = 9.8, 9.5 Hz, H-
or H-300 or H-400), 5.68 (1H, pt, J = 10.0, 9.9 Hz, H-200 or H-300 or
400), 5.20 (1H, d, J100 ,200 = 9.9 Hz, H-100), 4.67 (1H, dd, J500 ,600a = 2.6 Hz,
600a), 4.51 (1H, dd, J600a,600b = 12.5, J500 ,600b = 5.2 Hz, H-600b), 4.44–4.33
H, m, H-5’’, CH2CH3), 1.40 (3H, t, J = 7.2 Hz, CH2CH3). 13C NMR
DCl3, 90 MHz) d (ppm): 166.0, 165.6, 165.1, 165.0 (CO), 162.9,
1.0, 160.2 (oxadiazole, COOEt), 141.0 (triazole-C), 133.8–127.7
r, triazole CH), 77.1, 72.9, 71.7, 70.7, 68.7 (C-100-C-500), 62.8,
.3 (CH2, C-600), 44.2 (CH2), 14.2 (CH3). Anal. Calcd for
2H35N5O12 (801.75): C, 62.92; H, 4.40; N, 8.74. Found: C, 63.05;
4.56; N, 8.86.
.24. 2-(200,300,400,600-Tetra-O-benzoyl-b-D-glucopyranosyl)-5-(40-
droxymethyl-10,20,30-triazole-10-ylmethyl)-1,3,4-oxadiazole
1)
Prepared by general procedure 4.8.1 from 26 (224 mg,
2 mmol). Column chromatography (1:1 EtOAc–hexane) gave
(198 mg, 85%, conversion 96%) as a colourless syrup. Rf = 0.14
:1 EtOAc–hexane); [a]D = 69 (c 0.20, CHCl3); 1H NMR (CDCl3,
0 MHz) d (ppm): 8.03–7.79 (9H, m, Ar, triazole CH), 7.77–7.25
2H, m, Ar), 6.09 (1H, pt, J = 10.4, 9.2 Hz, H-200 or H-300 or H-400),
5–5.79 (3H, m, H-200 or H-300 or H-400, CH2), 5.73 (1H, pt,
10.8, 9.1 Hz, H-200 or H-300 or H-400), 5.19 (1H, d, J100 ,200 = 10.7 Hz,
100), 4.79 (2H, br s, CH2) 4.66 (1H, dd, J500 ,600a = 1.0 Hz, H-600a),
0 (1H, dd, J500 ,600b = 5.6 Hz, J600a,600b = 12.5 Hz, H-600b), 4.37–4.33
H, m, H-500), 4.06 (1H, s, OH); 13C NMR (CDCl3, 90 MHz) d
pm): 166.1, 165.6, 165.1, 165.0 (CO), 162.8, 161.5 (oxadiazole),
8.6 (triazole-C), 133.8–127.8 (Ar), 122.6 (triazole-CH), 77.1,
.1, 71.6, 70.6, 68.7 (C-100–C-500), 69.3 (CH2OH), 62.8 (C-600), 44.1
H2). Anal. Calcd for C40H33O10N5 (759.72): C, 63.24; H, 4.38; N,
2. Found: C, 63.36; H, 4.49; N, 9.15.
.25. 2-Phenyl-5-[(4-phenyl-1H-1,2,3-triazol-1-yl)methyl]-
,4-oxadiazole (52)
Prepared by general procedure 4.8.3 from 28 (250 mg,
4 mmol) and phenylacetylene (152 mg, 1.48 mmol) in the pres-
ce of CuSO45H2O (3 mg, 0.012 mmol), Na-L-ascorbate (10 mg,
5 mmol), and TMEDA (15 lL, 0.11 mmol) in 6 mL solvent mix-
re at rt for 2 h to give 52 (256 mg, 68%) as white crystals. Mp:
0–181 C; 1H NMR (CDCl3, 360 MHz) d (ppm): 5.93 (2H, s,
2), 7.26–7.55 (6H, m, H-300–H-500, H-3000–H-5000), 7.83 (2H, d,
6.9 Hz, H-2000, H-6000), 7.99–8.03 (3H, m, H-50, H-200, H-600). 13C
R (CDCl3, 90 MHz) d (ppm): 42.3 (CH2), 118.0 (C-4000), 121.0
-1000), 123.9 (C-2000, C-6000), 125.2 (C-200, C-600), 125.9 (C-50), 126.6
-400), 127.0 (C-3000, C-5000), 127.2 (C-300, C-500), 127.9 (C-100), 134.4
-40), 146.9 (C-2), 158.2 (C-5). Anal. Calcd for C17H13N5O
03.11): C, 67.32; H, 4.32; N, 23.09. Found: C, 67.39; H, 4.40; N,
.11.
.26. Ethyl 1-[(5-phenyl-1,3,4-oxadiazol-2-yl)methyl]-1H-
,3-triazole-4-carboxylate (53)
Prepared by general procedure 4.8.3 from 28 (500 mg,
8 mmol) ethyl propiolate (293 mg, 2.96 mmol) in the presence
CuSO45H2O (25 mg, 0.01 mmol), Na-L-ascorbate (79 mg,
0 mmol) in 12 mL solvent mixture at rt for 75 h to give 52
67 mg, 76%) as white crystals. Mp: 116–117 C; 1H NMR (CDCl3,
0 MHz) d (ppm): 1.39 (3H, t, J = 6.9 Hz, CH2–CH3), 4.42 (2H, q,
7,0 Hz, CH2–CH3), 5.13 (2H, s, CH2), 7.48–7.57 (3H, m, H-300, H-
, H-500), 8.02 (2H, d, J = 8.0 Hz, H-200, H-600), 8.40 (1H, s, H-50).
NMR (CDCl3, 360 MHz) d (ppm): 12.3 (CH2–CH3), 42.6 (CH2),
.6 (CH2–CH3), 120.8 (C-100), 125.2 (C-200, C-600) 126.1 (C-50),
7.3 (C-300, C-500), 130.6 (C-400), 139.2 (C-40), 157.6 (C-2), 158.2ease cite this article in press as: Kun, S.; et al. Carbohydr. Res. (2011), do-5), 164.4 (C@O). Anal. Calcd for C14H13N5O3 (299.10): C, 56.18;
4.38; N, 23.40. Found: C, 56.21; H, 4.39; N, 23.45.
.27. {1-[(5-Phenyl-1,3,4-oxadiazol-2-yl)methyl]-1H-1,2,3-
azol-4-yl}methanol (54)
Prepared by general procedure 4.8.3 from 28 (201 mg,
0 mmol) prop-2-yn-1-ol (67 mg, 1.2 mmol) in the presence of
SO45H2O (10 mg, 0.04 mmol), Na-L-ascorbate (21 mg,
6 mmol), and TMEDA (15 lL, 0.11 mmol) in 9 mL solvent mix-
re at rt for 3 h to give 54 (41 mg, 55%) as white crystals. Mp:
6–197 C; 1H NMR (CDCl3, 360 MHz) d (ppm): 4.56 (2H, d,
5.3 Hz, CH2–OH), 5.27 (1H, t, J = 5.8 Hz, OH), 6.1 (2H, s, CH2),
0–7.63 (3H, m, H-300–H-500), 7.97 (2H, d, J = 6.8 Hz, H-200, H-600),
2 (1H, s, H-50). 13C NMR (CDCl3, 90 MHz) d (ppm): 42.2 (CH2–
), 53.5 (CH2), 121.4 (C-100), 122.3 (C-50), 125.1 (C-200, C-600),
8.0 (C-300, C-500), 130.8 (C-400), 147.1 (C-40), 160.1 (C-5), 163.3
-2). Anal. Calcd for C12H11N5O2 (257.09): C, 56.03; H, 4.31; N,
.22. Found: C, 56.011; H, 4.38; N, 27.29.
.28. 2-{1-[(5-Phenyl-1,3,4-oxadiazol-2-yl)methyl]-1H-1,2,3-
azol-4-yl}propan-2-ol (55)
Prepared by general procedure 4.8.3 from 28 (250 mg,
4 mmol) 2-methylbut-3-yn-2-ol (125 mg, 1.49 mmol) in the
esence of CuSO45H2O (12 mg, 0.049 mmol), Na-L-ascorbate
0 mg, 0.20 mmol) in 9 mL solvent mixture at rt for 1.5 h to give
(306 mg, 86%) as white crystals. Mp: 164–166 C; 1H NMR
DCl3, 360 MHz) d (ppm): 1.45 (6H, s, 6H, CH3), 5.18 (1H, s, OH),
5 (2H, s, CH2), 7.57–7.59 (3H, m, H-300–H-500), 7.94 (2H, d,
6.9 Hz, H-200, H-600), 8.08 (1H, s, H-50). 13C NMR (CDCl3,
MHz) d (ppm): 29.1 (–C(CH3)2OH), 42.1 (CH2), 65.6 (–
CH3)2OH), 120.1 (C-50), 121.4 (C-100), 125.1 (C-200, C-600), 128.0
-300, C-500), 130.8 (C-400), 154.9 (C-40), 160.1 (C-5), 163.3 (C-2).
al. Calcd for C14H15N5O2 (285.12): C, 58.94; H, 5.30; N, 24.55.
und: C, 59.01; H, 5.38; N, 24.59.
.29. 2-Phenyl-5-[(4-trimethylsilyl-1H-1,2,3-triazol-1-
methyl]-1,3,4-oxadiazole (56)
Prepared by general procedure 4.8.3 from 28 (750 mg,
2 mmol) ethynyltrimethylsilane (439 mg, 4.47 mmol) in the
esence of CuSO45H2O (37 mg, 0.15 mmol), Na-L-ascorbate
20 mg, 0.60 mmol) in 27 mL solvent mixture at rt for 60 h to give
(1.090 g, 98%) as white crystals. Mp: 113–117 C; 1H NMR
DCl3, 360 MHz) d (ppm): 0.32 (9H, s, CH3), 5.92 (2H, s, CH2),
9–7.55 (3H, m, H-300, H-400, H-500), 7.77 (1H, s, H-50), 8.02 (2H,
J = 6.9 Hz, H-200, H-600). 13C NMR (CDCl3, 90 MHz) d (ppm): -3.1
H3), 41.5 (CH2), 121.0 (C-100), 125.2 (C-200,C-600), 127.2 (C-300, C-
), 127.4 (C-50), 130.4 (C-400), 146.0 (C-40), 158.4 (C-5), 164.2 (C-
. Anal. Calcd for C14H17N5OSi (299.12): C, 56.16; H, 5.72; N,.30. 5-Phenyl-2-[(1H-1,2,3-triazol-1-yl)methyl]-1,3,4-
adiazole (57)
Compound 56 (226 mg, 0.75 mmol) was dissolved in dry THF
mL) and a solution of TBAF (80 mg, 0.25 mmol) in THF
.25 mL) was added. The mixture was stirred at 50 C (bath temp)
r 1 h, and then TBAF (80 mg, 0.25 mmol) in THF (0.25 mL) was
ded again. After 4 h TLC (2:1 PhCH3–EtOAc) had indicated com-
etion of the transformation, the solvent was evaporated and the
sidue was puriﬁed by ﬂash chromatography (1:1 PhCH3–EtOAc)
give 57 (71 mg, 35%) as white crystals. Mp: 146–147 C; 1H
R (Me2SO-d6, 360 MHz) d (ppm): 5.92 (2H, s, CH2), 7.48–7.56
H, m, H-200–H-600), 7.81 (1H, d, J = 6.5 Hz, H-50), 8.01 (1H, d,
6.7, H-40). 13C NMR (Me2SO-d6, 90 MHz) d (ppm): 43.5 CH2),
0.0 (C-40), 122.8 (C-1’’), 125.7–129.1 (C-200–C-600), 133.8 (C-50),
1.4 (C-2), 164.7 (C-5). Anal. Calcd for C11H9N5O (227.08): C,
.14; H, 3.99; N, 30.82. Found: C, 58.22; H, 4.05; N, 30.90.i:10.1016/j.carres.2011.03.004
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15 March 20114.5.31. 3-(1-((5-Phenyl-1,3,4-oxadiazol-2-yl)methyl)-1H-1,2,3-
triazol-4-yl)benzenamine (58)
Prepared by general procedure 4.8.3 from 28 (250 m
1.24 mmol) 3-ethynylbenzenamine (174 mg, 1.49 mmol) in th
presence of CuSO45H2O (12.4 mg, 0.05 mmol), Na-L-ascorbat
(40 mg, 0.20 mmol), and TMEDA (15 lL, 0.11 mmol) in 10 mL so
vent mixture at rt for 28 h to give 58 (247 mg, 62%) as brown crys
tals. Mp: 175–177 C; 1H NMR (Me2SO-d6, 360 MHz) d (ppm): 5.2
(2H, vbr s, NH2), 6.17 (2H, s, CH2), 6.57 (1H, d, J = 4.7 Hz, H-6), 7.00
7.16 (3H, m, H-2, H-4, H-5), 7.61–7.63 (3H, m, H-3000, H-4000, H-5000
7.99–8.01 (2H, d, J = 5.4 Hz H-2000, H-6000), 8.65 (1H, s, H-50). 13
NMR (Me2SO-d6, 90 MHz) d (ppm): 43.9 (CH2), 110.5 (C-2), 113.
(C-4), 113.8 (C-6), 121.9 (C-5), 122.8 (C-100), 126.6 (C-200, C-600
129.3 (C-50), 129.4 (C-300, C-500), 130.6 (C-1), 132.2 (C-400), 147.
(C-40), 148.9 (C-3), 161.4 (C-500), 164.8 (C-200). Anal. Calcd fo
C17H14N6O (318.12): C, 64.14; H, 4.43; N, 26.40. Found: C, 64.25
H, 4.51; N, 26.48.
4.5.32. 2-(b-D-Glucopyranosyl)-5-(40-phenyl-10,20,30-triazole-10-
ylmethyl)-1,3,4-oxadiazole (59)
Prepared by general procedure 4.2 from 49 (131 m
0.16 mmol). Column chromatography (2:1 CHCl3–MeOH) gave 5
(40 mg, 63%) as a colourless syrup. Rf = 0.58 (2:1 CHCl3–MeOH
[a]D = +37 (c 0.19, MeOH); 1H NMR (CD3OD, 360 MHz) d (ppm
8.35 (1H, s, triazole), 7.84–7.82 (5H, m, Ph), 3.83 (1H, d
J100 ,200 = 10.4 Hz, H-100), 3.63 (1H, dd, J600a,600b = 11.8 Hz, J500 ,600a = 1.4 H
H-600a), 3.62 (1H, pt, J = 9.7, 8.7 Hz, H-200 or H-300 or H-400), 3.55 (1H
dd, J500 ,600a = 5.4 Hz H-600b), 3.48 (1H, pt, J = 9.3, 7.9 Hz, H-200 or H-300
or H-400), 3.52–3.38 (2H, m, H-200 or H-300 or H-400 and H-500), 3.36
(2H, s, CH2). 13C NMR (CD3OD, 90 MHz) d (ppm): 180.0, 175.4 (oxa-
diazole), 152.6 (triazole-C), 127.9 (triazole-CH) 133.2–127.5 (Ph),
82.3 (C-100), 80.4, 79.1, 73.4, 71.3 (C-200-C-500), 62.7 (C-600), 52.8
(CH2). Anal. Calcd for C17H19N5O6 (389.36): C, 52.44; H, 4.92; N,
17.99. Found: C, 52.37; H, 4.81; N, 17.87.
4.5.33. 2-(b-D-Glucopyranosyl)-5-(40-methoxycarbonyl-10,20,30-
triazole-10-ylmethyl)-1,3,4 oxadiazole (60)
Prepared by general procedure 4.2 from 50 (150 mg,
0.19 mmol). Column chromatography (9:1 CHCl3–MeOH) gave 60
(68 mg, 96%) as a colourless syrup. Rf = 0.08 (9:1 CHCl3–MeOH);
[a]D = +29 (c 0.21, MeOH); 1H NMR (CD3OD, 360 MHz) d (ppm):
8.49 (1H, s, triazole), 3.86 (1H, d, J100 ,200 = 10.5 Hz, H-100), 3.82 (1H,
dd, J6a00 ,600b = 11.6 Hz, J500 ,600a = 1.3 Hz, H-600a), 3.52 (1H, pt, J = 9.5,
8.5 Hz, H-200 or H-300 or H-400), 3.38 (s, 2H, CH2), 3.48 (1H, dd,
J500 ,600b = 5.2 Hz, H-600b), 3.33 (1H, pt, 8.2, 7.9 Hz, H-200 or H-300 or H-
400), 3.20–3.03 (2H, m, H-200 or H-300 or H-400 and H-500), 3.01 (3H,
s, CH3). 13C NMR (CD3OD, 90 MHz) d (ppm): 176.9, 173.8 (oxadiaz-
ole), 167.9 (CO), 150.6 (triazole-C), 125.4 (triazole-CH), 81.7 (C-100),
79.6, 75.1, 74.6, 72.3 (C-200-C-500), 62.2 (C-600), 51.2 (CH2), 42.7
(CH3). Anal. Calcd for C13H17 N5O8 (371.30): C, 42.05; H, 4.61; N,
18.86. Found: C, 42.17; H, 4.75; N, 18.92.
4.5.34. 2-(b-D-Glucopyranosyl)-5-(40-carboxyamido-10,20,30-
triazole-10-ylmethyl)-1,3,4-oxadiazole (61)
Oxadiazole 50 (105 mg, 0.13 mmol) was dissolved in methano-
lic ammonia solution (5 mL). After 48 h TLC (1:1 CHCl3–MeOH)
indicated completion of the transformation. The solvent was evap-
orated under reduced pressure. The crude product was puriﬁed by
column chromatography (2:1 CHCl3–MeOH) to give 61 (22 mg,
47%) as a colourless syrup. [a]D = +30.6 (c 0.20, MeOH); Rf = 0.21
(1:1 CHCl3–MeOH); 1H NMR (CD3OD, 360 MHz) d (ppm): 8.51
(1H, s, triazole), 7.85 (2H, s, NH2), 3.80 (1H, d, J100 ,200 = 10.5 Hz, H-
100), 3.85 (1H, dd, J600a,600b = 11.9 Hz, J500 ,600a = 1.3 Hz, H-600a), 3.78
(1H, pt, J = 9.5, 8.7 Hz, H-200 or H-300 or H-400), 3.69 (1H, dd,
J500 ,600b = 5.2 Hz, H-600b), 3.51 (1H, pt, J = 9.2, 7.9 Hz, H-200 or H-300 or
H-400), 3.43–3.33 (2H, m, H-200 or H-300 or H-400 and H-500), 3.25
t,
Please cite this article in press as: Kun, S.; et al. Carbohydr. Res. (201(2H, s, CH2). 13C NMR (CD3OD, 90 MHz) d (ppm): 177.6, 174.7 (oxa
diazole), 172.0 (CO), 151.8 (triazole-C), 128.5 (triazole-CH), 82.
(C-100), 79.4, 79.2, 73.5, 70.9 (C-200–C-500), 62.2 (C-600), 43.0 (CH2
Anal. Calcd for C12H16N6O7 (356.29): C, 40.45; H, 4.53; N, 23.59
Found: C, 40.39; H, 4.62; N, 23.69.
4.5.35. 2-(b-D-Glucopyranosyl)-5-(40-hydroxymethyl-10,20,30-
triazol-10-ylmethyl)-1,3,4-oxadiazole (62)
Prepared by general procedure 4.2 from 51 (150 m
0.20 mmol). Column chromatography (1:1 CHCl3–MeOH) gave 6
(20 mg, 30%) as a colourless syrup. Rf = 0.58 (2:3 CHCl3–MeOH
[a]D = +28 (c 0.18, MeOH); 1H NMR (CD3OD, 360 MHz) d (ppm
4.70–4.66 (2H, m, CH2), 4.53 (1H, d, J100 ,200 = 10.6 Hz, H-100), 3.8
(1H, dd, J600a,600b = 11.9 Hz, J500 ,600a = 1.2 Hz, H-600a), 3.76–3.36 (5H, m
H-200, H-300, H-400, H-500, H-600b). 13C NMR (CD3OD, 90 MHz)
(ppm): 166.6, 165.4 (oxadiazole), 149.9 (triazole-C), 120.5 (tria
zole-CH), 82.9, 79.1, 74.5, 73.4, 71.3 (C-100-C-500), 62.8 (C-600), 45.
(CH2OH), 33.6 (CH2). Anal. Calcd for C12H17N5O7 (343.29): C
41.98; H, 4.99; N, 20.40. Found: C, 42.08; H, 5.11; N, 20.49.
4.5.36. 2-(b-D-Glucopyranosyl)-5-azidomethyl-1,3,4-oxadiazole
(63)
Prepared by general procedure 4.2 from 26 (150 m
0.21 mmol) for 2 h. Column chromatography (3:1 CHCl3–MeOH
gave 63 (50 mg, 82%) as a colourless syrup. Rf = 0.48 (7:3 CHCl3
MeOH); [a]D = +26.6 (c 0.20, MeOH); 1H NMR (CD3OD, 360 MHz
d (ppm): 4.70 (2H, s, CH2), 4.57 (1H, d, J10 ,20 = 10.6, Hz, H-10), 3.8
(1H, dd, J60a,60b = 11.9 Hz, J50 ,60a = 1.2 Hz, H-60a), 3.73 (1H, ps
J = 9.4 Hz, H-20 or H-30 or H-40), 3.67 (1H, dd, J60a,60b = 11.9,
J5,60b = 5.4 Hz, H-60b), 3.51–3.37 (3H, m, H-20 and/or H-30 and/or
1020H-40, H-50). 13C NMR (CD3OD, 90 MHz) d (ppm): 166.8, 163.6 (oxa-
diazole), 149.8 (triazole C), 125.1 (triazole CH), 82.9, 79.0, 74.5,
73.4, 71.2 (C-10–C-50), 73.2 (CH2–N3), 62.7 (C-60), 56.5 (CH2). Anal.
Calcd for C9H13O6N5 (287.23): C, 37.63; H, 4.56; N, 24.38. Found:
C, 38.11; H, 4.74; N, 24.65.
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